Search

Oxilofrine

Oxilofrine is used in combination with DB11609 as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

Sodium borate

Cytisine

Recent studies have shown it to be a more effective and significantly more affordable smoking cessation treatment than nicotine replacement therapy. … Recent Phase III clinical trials using Tabex (a brand of Cytisine marketed by Sopharma AD) have shown similar efficacy to varenicline, but at a fraction of the cost.

Coagulation factor X human

Coagulation Factor X (Human) solution is approved by the FDA for intravenous injection under the market name Coagadex which contains normally 100 IU/mL of coagulation Factor X derived from healthy donors

Osimertinib

[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.

Sodium phosphate, monobasic, unspecified form

Gilteritinib

[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.

Bacitracin

[A181952] Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748]

Levodopa

The first developed drug product that was approved by the FDA was a levodopa and carbidopa combined product called Sinemet that was approved on May 2, 1975[A177781,L6133].

Sotorasib

[A187547] Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 6, 2022.[L56070]